Article
Cell Biology
Yohei Kume, Hayato Go, Ryo Maeda, Kazuhide Suyama, Tsutomu Mori, Yukihiko Kawasaki, Koichi Hashimoto, Mitsuaki Hosoya
Summary: In this study, a mouse model of hemolytic uremic syndrome (HUS) induced by LPS/Stx2 was used. The results showed that LPS/Stx2 administration led to decreased urinary osmolality and urinary potassium, suggesting distal nephron disorders. Microarray analysis identified differentially expressed genes at 6 h and 72 h after LPS/Stx2 administration, with activation of TNFR1/2, iNOS, and IL-6 signaling observed at both time points. Additionally, pathways associated with lipid metabolism were inhibited at 72 h only. The downregulated genes were mainly expressed in the distal nephrons.
PHYSIOLOGICAL GENOMICS
(2022)
Article
Multidisciplinary Sciences
Julie Haendiges, Karen Jinneman, Narjol Gonzalez-Escalona
Summary: This study compared the performance of sequencing using different library preparation chemistries (Nextera XT and Nextera DNA Prep), and found that Nextera DNA Prep outperformed in sequence quality, assembly quality, and uniformity of genome coverage. Comprehensive detection of virulence genes is essential for assessing virulence potential.
Article
Urology & Nephrology
Gema Ariceta, Bradley P. Dixon, Seong Heon Kim, Gaurav Kapur, Teri Mauch, Stephan Ortiz, Marc Vallee, Andrew E. Denker, Hee Gyung Kang, Larry A. Greenbaum
Summary: Ravulizumab rapidly improved hematologic and kidney parameters in complement inhibitor-naive children with atypical hemolytic uremic syndrome, showing no unexpected safety concerns.
KIDNEY INTERNATIONAL
(2021)
Article
Urology & Nephrology
Manon Martins, Frank Bridoux, Jean Michel Goujon, Marie Sophie Meuleman, David Ribes, Eric Rondeau, Mary -Jane Guerry, Yahsou Delmas, Benedicte Levy, Didier Ducloux, Christine Kandel-Aznar, Awena Le Fur, Cyril Garrouste, Francois Provot, Jean -Baptiste Gibier, Eric Thervet, Patrick Bruneval, Marion Rabant, Alexandre Karras, Marie Agnes Dragon Durey, Veronique Fremeaux-Bacchi, Sophie Chauvet
Summary: Hemolytic uremic syndrome (HUS) with kidney involvement associated with monoclonal gammopathy is a rare condition that severely affects patients' quality of life. The complement system plays a role in the pathogenesis of this disease, but HUS associated with monoclonal gammopathy has distinct characteristics compared to atypical HUS.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Article
Chemistry, Multidisciplinary
Dhruv Patel, Madison Hansen, Christopher Lambert, Shruti Hegde, Harikrishnan Jayamohan, Bruce K. Gale, Himanshu Jayant Sant
Summary: This study presents an electrochemical biosensing method for the detection of Shiga toxins using silver nanoparticles and low-cost carbon electrodes. By modifying the electrode structure, sensitive and rapid detection of Shiga toxins was achieved within a short period of time. Compared to traditional methods, this biosensor demonstrated better linearity and lower standard deviation.
Article
Pediatrics
Melissa Muff-Luett, Keia R. Sanderson, Rachel M. Engen, Rima S. Zahr, Scott E. Wenderfer, Cheryl L. Tran, Sheena Sharma, Yi Cai, Susan Ingraham, Erica Winnicki, Donald J. Weaver, Tracy E. Hunley, Stefan G. Kiessling, Meredith Seamon, Robert Woroniecki, Yosuke Miyashita, Nianzhou Xiao, Abiodun A. Omoloja, Sarah J. Kizilbash, Asif Mansuri, Mahmoud Kallash, Yichun Yu, Ashley K. Sherman, Tarak Srivastava, Carla M. Nester
Summary: This study investigated the broader use and outcomes of pediatric patients exposed to eculizumab, revealing a significant number of patients receiving off-label indications for C5 blockade. Although adverse events related to the medication were low, the cohort mortality rate was relatively high. Prospective studies in homogeneous disease cohorts are needed to confirm the role of C5 blockade in kidney outcomes.
PEDIATRIC NEPHROLOGY
(2021)
Article
Immunology
Claudia E. Coipan, Ingrid H. Friesema, Maaike J. C. van den Beld, Thijs Bosch, Sabine Schlager, Menno van der Voort, Christina Frank, Christina Lang, Angelika Fruth, Eelco Franz
Summary: This study describes the recent detection of 3 Shiga toxin-producing enteroaggregative Escherichia coli O104:H4 isolates from patients and 1 from pork in the Netherlands that were genetically highly similar to isolates from the 2011 large-scale outbreak in Europe. Our findings highlight the importance of safeguarding food supply production chains to prevent future outbreaks.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Endocrinology & Metabolism
A. Salpietro, V Sinatra, V Mottola, A. Ceravolo, V Chirico, L. Colavita, G. Ceravolo, E. Gitto, C. Cuppari, R. Chimenz
Summary: HUS is a thrombotic microangiopathy characterized by thrombocytopenia, non-immune microangiopathic hemolytic anemia, and acute kidney injury. It can be classified into typical and atypical types, with common pathogenetic features including damage of endothelial cells, intravascular hemolysis, coagulation abnormalities, and microthrombus formation.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2022)
Article
Urology & Nephrology
Thomas Barbour, Marie Scully, Gema Ariceta, Spero Cataland, Katherine Garlo, Nils Heyne, Yosu Luque, Jan Menne, Yoshitaka Miyakawa, Sung-Soo Yoon, David Kavanagh
Summary: Ravulizumab demonstrates long-term efficacy and safety in adults with aHUS, providing additional clinical benefits beyond 6 months of treatment, with most adverse events occurring early during the initial evaluation period and decreasing over time.
KIDNEY INTERNATIONAL REPORTS
(2021)
Article
Immunology
Sophie Dennhardt, Wiebke Pirschel, Bianka Wissuwa, Diana Imhof, Christoph Daniel, Jan T. Kielstein, Isabel Hennig-Pauka, Kerstin Amann, Florian Gunzer, Sina M. Coldewey
Summary: Hemolytic-uremic syndrome (HUS) is a systemic complication of infections with Shiga toxin-producing Escherichia coli, characterized by microangiopathic hemolytic anemia and acute kidney injury. This study found that endogenous erythropoietin (EPO) levels were elevated in HUS patients and animal models. Administration of EPO and its analog pHBSP improved survival and attenuated renal oxidative stress in mice with HUS. Therefore, repurposing EPO for the treatment of hemolytic anemia in HUS should be further investigated in clinical trials.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ashmita Tontanahal, Vanessa Sperandio, Olga Kovbasnjuk, Sebastian Loos, Ann-Charlotte Kristoffersson, Diana Karpman, Ida Arvidsson
Summary: This study investigated the effect of immunoglobulins (IgG) treatment on a mouse model of E. coli O157:H7 infection. The results showed that IgG treatment improved survival, reduced intestinal and renal pathology, and improved kidney function in infected mice. It was also found that IgG bound to the virulence factor EspP, blocking its enzymatic activity and protecting the host from infection.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Kes H. Stevens, Laura M. Baas, Thea J. A. M. van der Velden, Romy N. Bouwmeester, Niels van Dillen, Eiske M. Dorresteijn, Arjan D. van Zuilen, Jack F. M. Wetzels, Marloes A. H. M. Michels, Nicole C. A. J. van de Kar, Lambertus P. van den Heuvel
Summary: In this study, researchers established a robust ex vivo model to measure complement deposition on human GMVECs, which can be used to study the pathophysiological mechanisms of aHUS or other diseases associated with endothelial complement activation.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Critical Care Medicine
Nobuyasu Awano, Taisuke Jo, Takehiro Izumo, Minoru Inomata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Hirokazu Urushiyama, Takahide Nagase, Hideo Yasunaga
Summary: This study investigated the effectiveness and safety of recombinant human soluble thrombomodulin (rTM) for the treatment of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). The results showed that adding rTM to high-dose methylprednisolone (mPSL) treatment did not improve outcomes for patients with severe respiratory failure.
JOURNAL OF INTENSIVE CARE
(2022)
Article
Urology & Nephrology
Mendy ter Avest, Hilbert Steenbreker, Romy N. Bouwmeester, Caroline Duineveld, Kioa L. Wijnsma, Lambertus P. W. J. van den Heuvel, Saskia M. C. Langemeijer, Jack F. M. Wetzels, Nicole C. A. J. van de Kar, Rob ter Heine, CUREiHUS Study Grp
Summary: This study investigated the effect of proteinuria on the pharmacokinetics of eculizumab. The findings suggest that patients with severe proteinuria have a higher risk of underexposure to eculizumab.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Hematology
Hideo Kato, Mao Hagihara, Nobuhiro Asai, Takumi Umemura, Jun Hirai, Nobuaki Mori, Yuka Yamagishi, Takuya Iwamoto, Hiroshige Mikamo
Summary: This meta-analysis evaluated the efficacy and safety of recombinant human soluble thrombomodulin (rhTM) therapy in patients with sepsis-induced DIC. The results showed that rhTM significantly reduced mortality and improved DIC resolution without increasing the risk of bleeding complications.
THROMBOSIS RESEARCH
(2023)